2026年1月1日起，强生将迎来重大重组！

药智医械12-06

近日，据外媒报道，其根据强生内部员工邮件得知，强生医疗科技正在实施一项组织重组，改变其业务部门的运营方式，将从2026年1月1日起，在全球范围内从区域模式转向业务部门主导的运营模式。图片来源：Latest Medical Device News on MassDevice此举将放弃传统的区域运营模式，在全球范围内转向业务单元主导的全新架构。这一调整标志着强生在提升组织敏捷性、深化专业聚焦和加速市场...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2589822165?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-06 10:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2589822165","market":"us","top_or_hot":-1,"title":"2026年1月1日起，强生将迎来重大重组！","media":"药智医械","content":"<div>\n<p>近日，据外媒报道，其根据强生内部员工邮件得知，强生医疗科技正在实施一项组织重组，改变其业务部门的运营方式，将从2026年1月1日起，在全球范围内从区域模式转向业务部门主导的运营模式。图片来源：Latest Medical Device News on MassDevice此举将放弃传统的区域运营模式，在全球范围内转向业务单元主导的全新架构。这一调整标志着强生在提升组织敏捷性、深化专业聚焦和加速市场...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206112621a726fbcb&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2026年1月1日起，强生将迎来重大重组！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2026年1月1日起，强生将迎来重大重组！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-06 10:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206112621a726fbcb&s=b><strong>药智医械</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，据外媒报道，其根据强生内部员工邮件得知，强生医疗科技正在实施一项组织重组，改变其业务部门的运营方式，将从2026年1月1日起，在全球范围内从区域模式转向业务部门主导的运营模式。图片来源：Latest Medical Device News on MassDevice此举将放弃传统的区域运营模式，在全球范围内转向业务单元主导的全新架构。这一调整标志着强生在提升组织敏捷性、深化专业聚焦和加速市场...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206112621a726fbcb&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0203345920.USD","symbol_name":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206112621a726fbcb&s=b","article_id":"2589822165","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206112621a726fbcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589822165","pubTimestamp":1764986478,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"本次重组对强生内部部门及多个领导层做出相对应的调整。据悉，该重组决定始于2024年初开始向更加去中心化、端到端运营模式转型的基础上作出的，当时，强生已将约3.5万名医疗科技员工转入各业务部门。10月14日，强生公布其2025年第三季度财报时，正式官宣其骨科业务板块的拆分决定，将在未来18至24个月内，将其骨科业务分拆为一家名为DePuy Synthes的独立公司。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","BK4007":"制药","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","BK4532":"文艺复兴科技持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1032466523.USD":"高盛全球多资产收益组合Acc","JNJ":"强生","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","BK4559":"巴菲特持仓","BK4504":"桥水持仓","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H"},"translate_title":"From January 1, 2026, Johnson & Johnson will usher in a major restructuring!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1.5},"content_text":"近日，据外媒报道，其根据强生内部员工邮件得知，强生医疗科技正在实施一项组织重组，改变其业务部门的运营方式，将从2026年1月1日起，在全球范围内从区域模式转向业务部门主导的运营模式。图片来源：Latest Medical Device News on MassDevice此举将放弃传统的区域运营模式，在全球范围内转向业务单元主导的全新架构。这一调整标志着强生在提升组织敏捷性、深化专业聚焦和加速市场响应方面迈出了决定性一步。本次重组对强生内部部门及多个领导层做出相对应的调整。部门调整中，外科和电生理事业部将建立独立的区域领导结构，其中外科业务将向外科事业部总裁Hani Abouhalka汇报，而电生理业务向电生理及神经血管事业部总裁Michael Bodner汇报。区域供应链团队也将迎来转型，由医疗科技供应链副总裁Luis Roman领导，并向其汇报。此外，强生还计划让企业职能部门逐步调整其现有结构，以最佳地支持新的运营模式。强生医疗科技对此还表示，本次转型不涉及对接客户的职位、美国商业结构（已按业务部门划分）、强生旗下已按此业务部门主导模式运营的视力保健、心脏康复或循环系统修复事业部的变动。并且，该系列变动不包含中国区业务。领导层调整中，强生将取消在各区域和市场的跨医疗科技领导团队，具体变动包括：强生医疗拉丁美洲副总裁Gustavo Gala，将转而负责监督运营模式变革的结构化实施；强生医疗亚太区总裁Vishnu Kalra，将担任独立后的骨科公司DePuy Synthes总裁一职；Vishnu Kalra将向全球总裁Namal Nawana汇报，而2026年起，所有除美国地区以外的骨科业务市场和区域负责人将向Vishnu Kalra汇报；强生医疗欧洲、中东及非洲区总裁Gavin Wood将支持本次重组过渡，直至2026年中。据悉，该重组决定始于2024年初开始向更加去中心化、端到端运营模式转型的基础上作出的，当时，强生已将约3.5万名医疗科技员工转入各业务部门。对于本次重组的新模式，强生在内部邮件中表示，新模式将由业务部门主导，这也将减少官僚主义，提高问责制和自主权，使强生更具竞争力。此外，值得注意的是，强生在今年还官宣了一项重大决策，其计划分拆其骨科业务DePuy Synthes，该拆分决定已于10月正式公布。10月14日，强生公布其2025年第三季度财报时，正式官宣其骨科业务板块的拆分决定，将在未来18至24个月内，将其骨科业务分拆为一家名为DePuy Synthes的独立公司。而上周，强生医疗科技美国骨科事业部总裁Leslie Storms在社交媒体软件上宣布于11月离职。Leslie Storms是强生的一员老将，其在强生任职时间已达18年。完成拆分后，强生将集中资源，更加专注于六个关键增长领域的发展，这六个领域分别是肿瘤学、免疫学、神经科学、心血管、外科以及视力相关业务。本次强生医疗的全面重组，也是其为应对未来十年行业挑战所做的关键布局。通过赋予业务单元更大的自主权和全球责任，激发内部创新活力，加快产品上市速度，并最终在心血管、外科及视力保健等核心领域巩固其市场领导地位。责任编辑丨木棉排版丨惜姌声明：本文仅作信息传递之目的，并不代表本平台观点，本文不是治疗方案推荐，也不构成投资建议。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间核实并处理。合作、投稿、开白请联系：马老师18323856316（同微信）扫码加入读者群药智医械","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589822165","isCrawlerRequest":true}